The United States Food and Drug Administration has approved two Ziihera-containing regimens for first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, giving Jazz Pharmaceuticals a broader role in a difficult-to-treat gastrointestinal cancer market. The decision also delivers an important validation and financial catalyst for Zymeworks, which originally discovered and developed zanidatamab before licensing commercial rights to partners. Ziihera, also known as zanidatamab-hrii, can now be used with tislelizumab and chemotherapy across eligible HER2-positive patients regardless of PD-L1 status, while a second regimen pairs Ziihera with chemotherapy in patients whose tumors are HER2 IHC 3+.
The approval represents Ziihera’s second United States regulatory authorization in less than two years and significantly moves the therapy upstream into first-line treatment. Ziihera was previously granted accelerated approval in November 2024 for adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer, meaning the latest decision expands zanidatamab from a relatively narrow later-line setting into a much larger treatment opportunity.
Why the FDA approval could reshape first-line HER2-positive gastroesophageal cancer treatment
Gastroesophageal adenocarcinoma includes cancers arising in the stomach, gastroesophageal junction and esophagus. Around 20% of patients have HER2-positive disease, while metastatic gastroesophageal adenocarcinoma continues to carry a poor prognosis despite advances in targeted therapy and immunotherapy. Zymeworks noted that more than 31,000 new stomach cancer cases are diagnosed annually in the United States and that five-year survival for metastatic gastroesophageal adenocarcinoma remains below 10%.
Zanidatamab is differentiated from conventional HER2-directed antibodies by its bispecific design. The drug binds to two distinct extracellular sites on HER2, an approach intended to produce stronger receptor clustering, internalization and immune-mediated tumor-cell killing. Zymeworks developed the molecule through its proprietary antibody-engineering platform before entering licensing agreements with Jazz Pharmaceuticals and BeOne Medicines for development and commercialization across different territories.
The broader of the two newly approved regimens combines Ziihera with Tevimbra, or tislelizumab-jsgr, and fluoropyrimidine- and platinum-containing chemotherapy. That regimen is approved for tumors testing either HER2 IHC 3+ or IHC 2+/ISH+, without restricting treatment according to PD-L1 expression. The chemotherapy-only Ziihera regimen is approved for patients with HER2 IHC 3+ disease.
The absence of a PD-L1 requirement for the immunotherapy-containing regimen could become commercially and clinically important because it broadens the population potentially eligible for the treatment combination. Investigators involved in the program have indicated that similar outcomes across PD-L1 subgroups support the possibility of using the regimen across a comparatively wide range of HER2-positive patients rather than limiting its use to patients with higher PD-L1 expression.
HERIZON-GEA-01 showed longer progression-free and overall survival with zanidatamab
The regulatory decision was supported by the Phase 3 HERIZON-GEA-01 trial, an international open-label study involving 914 previously untreated patients with centrally confirmed HER2-positive advanced gastroesophageal adenocarcinoma. Participants were randomized to zanidatamab plus tislelizumab and chemotherapy, zanidatamab plus chemotherapy, or trastuzumab plus chemotherapy, allowing the experimental regimens to be compared directly with an established HER2-directed treatment backbone.
At a median follow-up of 25.9 months, median progression-free survival reached 12.4 months in both zanidatamab-containing groups compared with 8.1 months for trastuzumab plus chemotherapy. The risk of disease progression or death was reduced by 37% with the zanidatamab, tislelizumab and chemotherapy regimen and by 35% with zanidatamab plus chemotherapy, with both comparisons meeting statistical significance.
The survival signal was particularly important for the immunotherapy-containing combination. Median overall survival reached 26.4 months with zanidatamab, tislelizumab and chemotherapy compared with 19.2 months for trastuzumab and chemotherapy, representing a 28% reduction in the risk of death. Zanidatamab plus chemotherapy produced median overall survival of 24.4 months, although that comparison had not reached statistical significance at the interim analysis.
The findings were published in The New England Journal of Medicine in May 2026, providing peer-reviewed support for a treatment effect that is now translating directly into regulatory practice. The trial remains ongoing, and further overall survival analyses could become important for determining how the chemotherapy-only regimen ultimately compares with the immunotherapy-containing approach.
Safety will remain an important consideration because the regimens combine multiple active therapies. Grade 3 or higher adverse events occurred in 83.3% of patients receiving zanidatamab, tislelizumab and chemotherapy, compared with 73.8% for zanidatamab plus chemotherapy and 74.5% for trastuzumab plus chemotherapy. Diarrhea was the most common high-grade adverse event and occurred more frequently in the zanidatamab-containing groups.
Zymeworks receives $250 million as Ziihera approval changes the financial equation
For Zymeworks, the FDA decision carries unusually direct financial consequences. The approval triggers a $250 million milestone payment from Jazz Pharmaceuticals, increasing cumulative upfront and milestone payments from the partnership to $650 million. Zymeworks remains eligible for as much as another $1.3 billion in regulatory and commercial milestones, together with tiered royalties ranging from 10% to 20% on Jazz Pharmaceuticals’ net zanidatamab sales in licensed territories.
The economics do not stop there. Under Zymeworks’ separate collaboration with BeOne Medicines, the company has already received $81 million in upfront and milestone payments and remains eligible for another $144 million plus tiered royalties of up to 19.5% on sales in BeOne Medicines’ territories. The structure gives Zymeworks exposure to zanidatamab’s commercial growth without requiring it to independently fund a global oncology sales organization.
That model is becoming increasingly central to Zymeworks’ strategy. Licensing income and royalties from partnered products can provide non-dilutive financing for its wholly owned pipeline, which includes next-generation trispecific T-cell engagers and antibody-drug conjugates. Additional zanidatamab indications could therefore have a double effect by expanding royalty revenue while supplying capital for internally controlled programs.
Zanidatamab is also being studied across additional HER2-expressing tumors, including colorectal cancer, while Jazz Pharmaceuticals and BeOne Medicines continue broader clinical and regulatory development. Each additional successful indication could increase the drug’s addressable market and further strengthen the economics of Zymeworks’ royalty-based model.
Zymeworks stock slips after approval as investors digest a heavily anticipated catalyst
Zymeworks shares were trading around $28.17 at 10:56 a.m. Eastern on August 25, down approximately 2.1% from the previous close of $28.77 despite the FDA approval. The decline follows a substantial run ahead of the regulatory decision, including a 7.9% gain on August 21 and gains across much of the preceding week. The stock recently reached a 52-week high near $29.75, compared with a low of $13.60 over the same period.
The initial negative reaction therefore does not necessarily indicate that investors view the approval unfavorably. Expectations were elevated ahead of the August 25 Prescription Drug User Fee Act date, with Zymeworks shares rising as investors positioned for the anticipated $250 million milestone. The post-decision move has characteristics of a sell-the-news reaction, with some investors apparently locking in gains after the binary regulatory catalyst was resolved.
Longer-term sentiment remains tied less to the one-day share-price reaction and more to how rapidly Ziihera penetrates first-line HER2-positive gastroesophageal adenocarcinoma. The pivotal study produced a meaningful progression-free survival benefit and, with the tislelizumab-containing regimen, a statistically significant overall survival advantage against trastuzumab plus chemotherapy. Those data provide Jazz Pharmaceuticals with a strong clinical foundation for commercialization while giving Zymeworks a growing royalty stream and immediate non-dilutive capital.
The FDA approval consequently changes the zanidatamab story from one centered largely on development potential to one increasingly dependent on execution. Ziihera now has two United States indications, a first-line opportunity in a substantially broader cancer population and continuing development across additional tumors. For Zymeworks, the next phase will be measured not simply by regulatory milestones but by prescription growth, additional approvals and the scale of recurring royalties that its partnered oncology asset can ultimately generate.
